- Home
- RSVR vs CVAC Comparison
RSVR vs CVAC Comparison
Compare RSVR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | CVAC |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RSVR | CVAC |
|---|---|---|
| Price | $7.47 | $4.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $11.50 | $6.83 |
| AVG Volume (30 Days) | 68.8K | ★ 1.2M |
| Earning Date | 02-04-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | 0.15 | ★ 0.94 |
| Revenue | ★ $166,320,844.00 | $83,000,117.00 |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $5.37 | $23.71 |
| P/E Ratio | $51.46 | ★ $4.83 |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $6.56 | $2.48 |
| 52 Week High | $9.19 | $5.72 |
Technical Indicators
Market Signals| Indicator | RSVR | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 48.10 |
| Support Level | $7.43 | $4.26 |
| Resistance Level | $7.59 | $4.36 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 23.08 | 57.32 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.